DH drug pricing plans 'lack clarity'
By Stephen Robinson, 16 January 2013
Government plans to overhaul the NHS pricing system for new drugs are poorly explained, leaving clinicians, patients and the drug industry in the dark over how the changes will work, according to a highly critical report by MPs.
The House of Commons health select committee said it was 'unacceptable' that proposed value-based pricing changes were still not explained despite government plans to implement the measures in less than 12 months.
The committee of MPs called for the issue to be resolved by March. The DH said negotiations with the pharmaceutical industry over the plans were ongoing.
The verdict forms part of a report by the committee on the future role of NICE, which will take on a greater role in health and social care from April.
At present, NICE assesses whether the NHS should fund new medicines and technologies based on the manufacturer's price. The government wants to replace this with 'value-based pricing' - a system that determines a price the NHS is willing to pay based on the perceived value of a medicine.
'Decisions need to be taken'
But MPs said that after consulting on the plans in December 2010, little else had been clarified about how the system will work in practice.
Committee chair Stephen Dorrell MP (Con, Charwood), said the lack of clarity had 'persisted for too long'.
He said: 'Decisions need to be taken, and the details of the scheme made public to avoid problems with the transition to the new system at the beginning of 2014.
'We hope the government will respond positively to our suggestion that this situation should be clarified before the end of March this year.'
NHS Confederation chief executive Mike Farrar said: 'We need strong evidence to show that changes to the system will deliver maximum benefit to patients, without creating significant additional costs for commissioners or taxpayers.'
A DH spokesman said: 'Making sure patients get better access to innovative and effective drugs and treatments is a priority of this government. We want to do that by linking the price the NHS pays for new medicines to their value to NHS patients and society.
The spokesman added that negotiations with the Association of the British Pharmaceutical Industry (ABPI) were ongoing, and that it would respond formally to the MPs' report in due course.
MPs also called for an analysis of the outcomes of patients recieving treatment through the Cancer Drug Fund to assess the impact of the scheme. Any evidence of benefit should be built on when constructing the new drug pricing plans, they said.
- Industry issues drug price warning ahead of talks with DH
- Exclusive: NICE looks to future as an era ends
- Health secretary says GPs have 'ethical duty' to save NHS costs
- Health Bill reforms 'will fuel drug access inequality', warns NHS adviser
- NHS must be 'bullish' on the valuation of branded drugs
- NHS panel defines rules for rationing decisions
Send to a friend
Latest jobs Jobs web feed
- Salaried GP with a view to Partnership The Higham Ferrers Surgery Salary negotiable , Higham Ferrers, Northamptonshire
- Partnership Opportunity Leen View Surgery Negotiable, East Midlands
- Part-time Partner Taff Riverside Practice Share of the profit, Position in Cardiff
- Full Time Salaried GP Daneshouse Medical Centre Salary dependant on qualifications and experience, Burnley, Lancashire
- Salaried GP The Elms Medical Centre Negotiable depending upon experience, newly qualified starting at circa £72k pro-rata., North West England
- SALARIED GP (female) Mount Pleasant and Earlsheaton Medical Centres Dependent upon experience, Dewsbury / Batley, West Yorkshire
- Hunt to reveal GP reforms and new inspection regime
- LMCs demand emergency vote after Hunt out-of-hours comments
- GP contract 'not to blame' for A&E pressure, NHS leaders say
- GPC chairman warns GPs are 'strained beyond endurance'
- Hunt 'must recognise growing GP crisis', warns RCGP
- GP-patient relationship faces 'unprecedented strain'
MIMS Drug Search
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.